Hydralazine Amdipharm Uk (Hydralazine Hydrochloride)

Hydralazine Amdipharm UK is indicated for specific cardiovascular conditions where reduction of peripheral vascular resistance is desired.

• Hypertension that is not adequately controlled with first‑line agents.
• Congestive heart failure, typically as part of combination therapy.
• Hypertensive emergencies when rapid arterial dilation is required.
• Use in pregnancy‑associated hypertension under specialist guidance.
• Management of severe pre‑eclampsia in a hospital setting.

• Hydralazine hydrochloride acts directly on arteriolar smooth muscle by interfering with calcium influx and promoting nitric oxide‑mediated relaxation. This vasodilatory effect reduces systemic vascular resistance, leading to a decrease in afterload and arterial blood pressure. The drug does not significantly affect venous capacitance, and its action is independent of beta‑adrenergic receptors, allowing it to complement other antihypertensive agents and improve cardiac output.

Like all vasodilators, hydralazine may cause a range of adverse reactions, varying from mild to potentially serious.

Common

• Headache, often described as throbbing and may improve with rest.
• Flushing or a sensation of warmth, typically affecting the face and neck.
• Tachycardia, an increase in heart rate that can be felt as palpitations.
• Nausea or vomiting, occasionally accompanied by mild abdominal discomfort.

Serious

• Lupus‑like syndrome, presenting with joint pain, muscle aches, and a photosensitive rash.
• Severe hypotension, causing marked dizziness, fainting, or loss of balance.
• Rapid worsening of heart failure, indicated by sudden swelling, shortness of breath, or pulmonary edema.

Before initiating therapy with Hydralazine Amdipharm UK, several safety considerations should be reviewed.

• Assess baseline blood pressure and heart rate to avoid excessive hypotension.
• Evaluate for a history of systemic lupus erythematosus or drug‑induced lupus.
• Use caution in patients with coronary artery disease, as reflex tachycardia may increase myocardial oxygen demand.
• Monitor renal and hepatic function periodically during long‑term treatment.
• Pregnant women (Category B) should only use the drug when benefits outweigh potential risks.
• Elderly patients may be more sensitive to dose‑related side effects and may require lower initial doses.

Hydralazine can interact with several medications, influencing its efficacy or increasing the risk of adverse effects.

Avoid

• Concurrent use with other direct vasodilators (e.g., nitroglycerin) due to additive hypotensive risk.
• Combining with beta‑blockers without careful monitoring, as reflex tachycardia may be blunted.
• Co‑administration with monoamine oxidase inhibitors (MAOIs) can precipitate severe hypertension.

Use with caution

• Diuretics, especially loop diuretics, may enhance orthostatic hypotension; monitor fluid status.
• Calcium channel blockers, which may increase the likelihood of reflex tachycardia.
• NSAIDs, which can reduce the antihypertensive effect of hydralazine.